Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin

SIMPLE SUMMARY: Unresectable or metastatic biliary tract cancer (BTC) has a poor prognosis with the standard gemcitabine and cisplatin (GemCis) regimen. Given the considerable incidence of HER2-overexpressing tumours (e.g., >10% of gallbladder cancer), HER2 is a potential therapeutic target in ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Hyehyun, Jeong, Jae Ho, Kim, Kyu-Pyo, Lee, Sang Soo, Oh, Dong Wook, Park, Do Hyun, Song, Tae Jun, Park, Yangsoon, Hong, Seung-Mo, Ryoo, Baek-Yeol, Yoo, Changhoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825072/
https://www.ncbi.nlm.nih.gov/pubmed/33418871
http://dx.doi.org/10.3390/cancers13020161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825072/
https://www.ncbi.nlm.nih.gov/pubmed/33418871
http://dx.doi.org/10.3390/cancers13020161

Ejemplares similares